Market Cap : 2.32 B | Enterprise Value : 2.19 B | PE Ratio : At Loss | PB Ratio : |
---|
NAS:PTCT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:PTCT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
PTC Therapeutics's Total Assets for the quarter that ended in Mar. 2022 was $1,799.6 Mil.
Warning Sign:
If a company builds asset at 89.3% a year, faster than its revenue growth rate of 19% over the past 5 years, it means that the company may be getting less efficent.
During the past 12 months, PTC Therapeutics's average Total Assets Growth Rate was 7.90% per year. During the past 3 years, the average Total Assets Growth Rate was 9.30% per year. During the past 5 years, the average Total Assets Growth Rate was 89.30% per year. During the past 10 years, the average Total Assets Growth Rate was 78.70% per year.
During the past 11 years, PTC Therapeutics's highest 3-Year average Total Assets Growth Rate was 223.40%. The lowest was 4.60%. And the median was 67.60%.
Total Assets is connected with ROA %. PTC Therapeutics's annualized ROA % for the quarter that ended in Mar. 2022 was -27.12%. Total Assets is also linked to Revenue through Asset Turnover. PTC Therapeutics's Asset Turnover for the quarter that ended in Mar. 2022 was 0.08.
The historical data trend for PTC Therapeutics's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Assets are all the assets a company owns.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
PTC Therapeutics's Total Assets for the fiscal year that ended in Dec. 2021 is calculated as
Total Assets | = | Total Equity (A: Dec. 2021 ) | + | Total Liabilities (A: Dec. 2021 ) |
= | 1.438 | + | 1936.618 | |
= | 1,938.1 |
PTC Therapeutics's Total Assets for the quarter that ended in Mar. 2022 is calculated as
Total Assets | = | Total Equity (Q: Mar. 2022 ) | + | Total Liabilities (Q: Mar. 2022 ) |
= | -90.581 | + | 1890.172 | |
= | 1,799.6 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Assets is connected with ROA %.
PTC Therapeutics's annualized ROA % for the quarter that ended in Mar. 2022 is
ROA % | = | Net Income (Q: Mar. 2022 ) | / | ( (Total Assets (Q: Dec. 2021 ) | + | Total Assets (Q: Mar. 2022 )) | / count ) |
= | -506.904 | / | ( (1938.056 | + | 1799.591) | / 2 ) | |
= | -506.904 | / | 1868.8235 | ||||
= | -27.12 % |
Note: The Net Income data used here is four times the quarterly (Mar. 2022) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
PTC Therapeutics's Asset Turnover for the quarter that ended in Mar. 2022 is
Asset Turnover | ||||||
= | Revenue (Q: Mar. 2022 ) | / | ( (Total Assets (Q: Dec. 2021 ) | + | Total Assets (Q: Mar. 2022 )) | / count ) |
= | 148.735 | / | ( (1938.056 | + | 1799.591) | / 2 ) |
= | 148.735 | / | 1868.8235 | |||
= | 0.08 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Thank you for viewing the detailed overview of PTC Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Southwell David P | director | C/O INOTEK PHARMACEUTICALS CORPORATION 91 HARTWELL AVENUE LEXINGTON MA 02421 |
Jacobson Allan Steven | director | PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Peltz Stuart Walter | director, officer: Chief Executive Officer | PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Utter Christine Marie | officer: SVP, Finance & CAO | C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Boulding Mark Elliott | officer: Exec. VP and CLO | C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Hill Emily Luisa | officer: Chief Financial Officer | C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Svoronos Dawn | director | C/O MEDIVATION, INC. 525 MARKET ST., 36TH FLOOR SAN FRANCISCO CA 94105 |
Pauwels Eric | officer: Chief Business Officer | 550 HILLS DRIVE BEDMINSTER NJ 07921 |
Klein Matthew B. | officer: Chief Development Officer | C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Schmertzler Michael | director | 1300 VALLEY ROAD NEW CANAAN CT 06840 |
Souza Marcio | officer: Chief Operating Officer | C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Almstead Neil Gregory | officer: Chief Technical Ops Officer | C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Reeve Emma | director | C/O PAREXEL INTERNATIONAL CORPORATION 195 WEST STREET WALTHAM MA 02451 |
Steele Glenn Jr Md Phd | director | 250 TECHNOLOGY PARK LAKE MARY FL 32746-6232 |
Zeldis Jerome B | director | 8767 E. VIA DE VENTURA, SUITE 190 SCOTTSDALE AZ 85258 |
From GuruFocus
Other Sources
By Zacks 2020-08-18
By Seekingalpha 2021-02-26
By Zacks 2022-02-18
By Zacks 2022-02-22
By Zacks 2022-03-14
By Zacks 2021-03-30
By Zacks 2021-10-21
By Seekingalpha 2021-10-29
By Seekingalpha 2021-01-20
By Seekingalpha 2020-09-30
By Seekingalpha 2020-10-30
By Zacks 2021-05-27
By Zacks 2021-02-25